Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 4/2018

01-08-2018 | Case Report

Gamma delta T cell expansion in Whipple’s disease with muscular granulomatous vasculitis

Authors: Didier Brönnimann, Marie-Anne Vandenhende, Jean-François Viallard

Published in: Infection | Issue 4/2018

Login to get access

Abstract

Whipple’s disease usually presents as chronic joint pain followed by digestive manifestations. However, many different presentations have been described in the literature. We report here the first proven case of muscular vasculitis related to Whipple’s disease, associated with an expansion of circulating activated γδ T lymphocytes.
Literature
1.
Schneider T, Moos V, Loddenkemper C, Marth T, Fenollar F, Raoult D. Whipple’s disease: new aspects of pathogenesis and treatment. Lancet Infect Dis. 2008;8:179–90.CrossRefPubMed
2.
Al-Hamoudi W, Habbab F, Nudo C, Nahal A, Flegel K. Eosinophilic vasculitis: a rare presentation of Whipple’s disease. Can J Gastroenterol J Can Gastroenterol. 2007;21:189–91.CrossRef
3.
Peters G, du Plessis DG, Humphrey PR. Cerebral Whipple’s disease with a stroke-like presentation and cerebrovascular pathology. J Neurol Neurosurg Psychiatry. 2002;73:336–9.CrossRefPubMedPubMedCentral
4.
5.
Puget M, Iwaz J, Tristan A, Streichenberger N. Whipple’s disease with muscle impairment. Muscle Nerve. 2006;34:794–8.CrossRefPubMed
6.
Agard C, Brisseau J-M, Grossi O, Pattier S, Espitia-Thibault A, Le Goff B, et al. Two cases of atypical Whipple’s disease associated with cytoplasmic ANCA of undefined specificity. Scand J Rheumatol. 2012;41:246–8.CrossRefPubMed
7.
Hayday AC. γδ cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000;18:975–1026.CrossRefPubMed
8.
Bank I, Marcu-Malina V. Quantitative peripheral blood perturbations of γδ T cells in human disease and their clinical implications. Clin Rev Allergy Immunol. 2014;47:311–33.CrossRefPubMed
9.
Gu S, Nawrocka W, Adams EJ. Sensing of pyrophosphate metabolites by Vγ9Vδ2 T cells. Front Immunol. 2014;5:688.PubMed
10.
Kowalczewska M, Villard C, Lafitte D, Fenollar F, Raoult D. Global proteomic pattern of Tropheryma whipplei: a Whipple’s disease bacterium. Proteomics. 2009;9:1593–616.CrossRefPubMed
11.
Lagier J-C, Fenollar F, Lepidi H, Raoult D. Evidence of lifetime susceptibility to Tropheryma whipplei in patients with Whipple’s disease. J Antimicrob Chemother. 2011;66:1188–9.CrossRefPubMed
12.
Kroca M, Tärnvik A, Sjöstedt A. The proportion of circulating gammadelta T cells increases after the first week of onset of tularaemia and remains elevated for more than a year. Clin Exp Immunol. 2000;120:280–4.CrossRefPubMedPubMedCentral
Metadata
Title
Gamma delta T cell expansion in Whipple’s disease with muscular granulomatous vasculitis
Authors
Didier Brönnimann
Marie-Anne Vandenhende
Jean-François Viallard
Publication date
01-08-2018
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 4/2018
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-018-1143-3

Other articles of this Issue 4/2018

Infection 4/2018 Go to the issue

Case Report

A case of acute hepatitis A infection in an HIV-positive patient despite complete hepatitis A vaccination

Original Paper

Cascade of care and factors associated with virological suppression among HIV-positive persons linked to care in the Test and Keep in Care (TAK) project

Original Paper

Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome

Case Report

Rickettsia parkeri infections diagnosed by eschar biopsy, Virginia, USA

Original Paper

Human cystic echinococcosis in Hungary (2000–2014): a retrospective case series analysis from a single-center study

Case Report

Gonococcal cellulitis: an (un)friendly bite
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits